Why every screening test trades benefit against harm
No cancer screening test is purely beneficial. Each carries some combination of false positives (leading to anxiety and follow-up procedures), false negatives, overdiagnosis (detecting cancers that would never have caused harm), and procedural risk. The question for any test is whether the lives extended outweigh the harms across the screened population, and that balance depends heavily on how common and how lethal the cancer is in the group being screened.
Mammography, colonoscopy, low-dose CT for lung cancer, and PSA testing for prostate cancer sit at different points on this tradeoff. Colorectal screening has relatively strong evidence because it can remove precancerous polyps before they become cancer. PSA testing is more contested because prostate cancer is often slow-growing, so screening detects many cancers that would never have shortened life.
Reading number needed to screen and NNT
Number needed to screen or treat expresses how many people must undergo a test or intervention for one to benefit. A larger number means most participants get no benefit while still being exposed to potential harms. These figures vary by age, baseline risk, and the trial they come from, so any single number is an estimate within a range rather than a fixed value.
Overdiagnosis is the subtlest harm: a screen-detected cancer that is real under the microscope but would never have progressed still leads to real treatment, with real side effects. This is why guidelines increasingly frame screening as a shared decision rather than a universal recommendation.
A note on applying this to yourself
This is general educational information, not medical advice. Screening recommendations differ by country and by guideline body, and individual decisions should weigh personal and family risk with a clinician. The diagram illustrates the general shape of the tradeoffs, not a recommendation for any specific person.